CD47 and cancer: Immunotherapy specifically interrupting CD47/SIRPα communication, namely, anti-CD47 monoclonal antibody Hu5F9-G4, is currently under six clinical trials and has emerged as a breakthrough in cancer treatment for solid and hematological tumors [21].